Enabling Cutting-Edge Technologies That Will Help Shape Our Future
2123 Frontiers uses our research, experts, and gatherings to take a systems approach to “enable” current cutting-edge technologies in science, engineering, medicine and technology.
Defining a frontier or breakthrough is no easy feat, but at its core, we believe these are “significant” advancements with the potential to create a positive impact on humanity. Honestly, some of them will work, and many may not. Some will be quick; some will take decades. The most important thing is to have the aspiration to change the trajectory of societal impact.
We believe this magic happens at the intersection of science, medicine, business, and engineering, driven by leaders who have the boldness, resilience, and persistence to push the envelope on new frontiers and drive breakthroughs!! Our platform brings together driven entrepreneurs, innovators, pioneers, and visionaries, all with a common purpose — “enabling” breakthroughs as we collectively push society’s frontiers.
Our Frontiers
Healthcare & Life Sciences
The pace of medical innovation continues to accelerate with new ideas being pursued. Scientists are focused on several major areas of unmet need from rare diseases (Huntington’s disease, sickle cell anemia) to neurological conditions (Alzheimer's, Parkinson's, Epilepsy) to oncology (pancreatic cancer, lung cancer, colorectal cancer) and metabolic health (diabetes, obesity, hormonal conditions).
Scientists have been making significant progress on many new tools and foundational capabilities e.g. gene editing, pharmacogenomics, personalized medicine, predictive analysis, novel biomarkers, implantable/wearable devices, tissue cell engineering. These new diagnostics, devices, drugs, and software/AI will allow us to better tackle some of the most impactful diseases in medicine.
We want to enable innovators, scientists, physicians, investors and entrepreneurs to accelerate the pace of medical innovation for humanity.
High Tech
Solutions that improve data structure, data architecture models, and data related technologies such as generative AI, large language models, cloud-native data, real time data processing are foundational.
Advancement in computation such as hardware advancement (quantum computing, semiconductors), software, and algorithms (high performance computing, quantum algorithms) are enabling the processing of larger amounts of data.
Spatial computing, Augmented reality (AR), Virtual reality (VR) and mixed reality is considered the next big paradigm shift in computing, enabling human-computer interaction to take place in the real world, in and around natural bodies and physical environments.
Innovations in robotics such as soft robotics, autonomous systems, human-robot interactions, bio-inspired robotics and AI and robotics integration have wide-ranging applications in a variety of industries such as healthcare, manufacturing, education.
To enable the secure implementation of technology, advances in cybersecurity tools such as zero trust architecture, next generation cloud workforce protection, password-less authentication, blockchain, quantum computing as well as ethical and legal guidelines must be put into place.
All these innovations will contribute to transformation in every industry and bringing us closer to a reality once only imagined!
Company Spotlight: TRIO Pharmaceuticals
Overview: TRIO Pharmaceuticals, a San Francisco based immuno-oncology startup founded in 2020, has engineered a first-in-class dual action bispecific antibody-drug conjugate (ADC) that simultaneously kills tumor cells and immunosuppressor cells to dismantle the immunosuppressive environment protecting the tumor, in a single molecule, addressing a critical limitation that has stalled checkpoint inhibitors for years.
Key Scientific Highlights:
First-in-Class Dual Action Bispecifc ADC: TRIO’s TIE-ADC™ (Tumor Immunity Enhancing ADC) platform, in which arm 1 binds to an antigen on the tumor cell and arm 2 binds to targets on immunosuppressive cells, which in turn helps overcome blocked T-cell function in the tumor microenvironment (TME).
Durable Response: The dual mechanism reprograms the immunosuppressive TME into an immune-permissive state, enabling durable anti-tumor immunity.
Combination with existing therapies: The mechanistic immunomodulation of the TME and the resulting increase in immune-permissiveness creates a synergistic foundation for combination with existing IO therapies including PD-1/PD-L1 inhibitors (Keytruda, Opdivo), BiTEs, and IL-2 therapies.
Plug and Play Architecture: Enables rapid interchange of tumor antigens (TROP2, HER2, FOLR1, and others) and immunosuppressor cell antigens (CD33, CSF1R, SEMA4A, and others) to rapidly create a large library of molecules.
Leadership: Patrick Doyle (CEO); Shiva Bhowmik PhD (CSO); William Grossman, MD, PhD (Consulting CMO) and Mikael Dolsten, MD, PhD (Board Chair).
Financials: $6.5M raised through a combination of seed funding and non-dilutive grants. Investors include SeedFolio, NuFund Venture Group, Friedman BioVentures, Purdue Ventures and Multiple Myeloma Investment Fund. Raising $40M Series A.
Upcoming Milestones:
Current: CMC development and cGMP scale-up underway in collaboration with Ajinomoto Bio-Pharma Services and Abzena.
2H 2027: IND filing for lead TROP2/CD33 TIE-ADC™ program in TROP2-expressing solid tumors.
1H 2028: Phase 1 trial initiation. Series A capital to deliver Phase 1/2 POC in lead program and pipeline expansion. First-in-human data expected within 18 months post-financing.
PLATFORM EXPANSION: Extension to a second indication enabling pharma partnership and out-licensing.
2123 Frontiers Salon
An engaging evening of conversation, connection, advise shared over some amazing updates from the Biotech featured on the 2123 Frontiers platform, Reverb Therapeutics, Neuropeutics Inc, Aveta Biomics Inc and Switchback Therapeutics.
